A PHASE I DOSE ESCALATION AND EXPANSION STUDY OF INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：1

作者：

Eigentler, Thomas ^{[1
]}

Heinzerling, Lucie ^{[2
]}

Krauss, Juergen ^{[3
]}

Weishaupt, Carsten ^{[4
]}

Mohr, Peter ^{[5
]}

Ochsenreither, Sebastian ^{[6
]}

Terheyden, Patrick ^{[7
]}

Martin-Liberal, Juan ^{[8
]}

Oliva, Marc ^{[8
]}

Lebbe, Celeste ^{[9
]}

Fluck, Michael ^{[10
]}

Brossart, Peter ^{[11
]}

Trigo Perez, Jose Manuel ^{[12
]}

Bauernfeind, Franz-Georg ^{[11
]}

Kays, Sarah-Katharina ^{[13
]}

Seibel, Tobias ^{[13
]}

Schoenborn-Kellenberger, Oliver ^{[13
]}

Stosnach, Claudia ^{[13
]}

Daehling, Angelika ^{[13
]}

Schmitt-Bormann, Beate ^{[13
]}

Gnad-Vogt, Ulrike ^{[13
]}

机构：

[1] Univ Med Ctr Tubingen, Tubingen, Germany

[2] Univ Erlangen Nurnberg, Erlangen, Germany

[3] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[4] Univ Munster, Munster, Germany

[5] Elbe Med Ctr, Buxtehude, Germany

[6] Charite Campus Benjamin Franklin, Berlin, Germany

[7] Univ Lubeck, Lubeck, Germany

[8] Hosp Duran & Reynals, Barcelona, Spain

[9] Hop St Louis, Paris, France

[10] Fachklin Hornheide, Munster, Germany

[11] Univ Clin Bonn, Bonn, Germany

[12] Hosp Clin V de la Victoria, Malaga, Spain

[13] CureVac AG, Tubingen, Germany

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0800

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

800

引用

页码：A478 / A479

页数：2

共 50 条

[1] A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors
Eigentler, Thomas
Krauss, Juergen
Schreiber, Jutta
Weishaupt, Carsten
Terheyden, Patrick
Heinzerling, Lucie
Mohr, Peter
Weide, Benjamin
Ochsenreither, Sebastian
Becker, Juergen
Bauernfeind, Franz-Georg
Brossart, Peter
Funkner, Fatma
Heidenreich, Regina
Kays, Sarah-Katharina
Muth, Anke
Seibel, Tobias
Scheel, Birgit
Schoenborn-Kellenberger, Oliver
Stosnach, Claudia
Daehling, Angelika
Strack, Tanja
Korolkiewicz, Roman
Gnad-Vogt, Ulrike
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2] A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.
Eigentler, Thomas
Bauernfeind, Franz G.
Becker, Jurgen C.
Brossart, Peter
Fluck, Michael
Heinzerling, Lucie
Krauss, Jurgen
Mohr, Peter
Ochsenreither, Sebastian
Schreiber, Jutta Sylvina
Terheyden, Patrick
Weide, Benjamin
Weishaupt, Carsten
Funkner, Fatma
Muth, Anke
Kays, Sarah-Katharina
Stosnach, Claudia
Daehling, Angelika
Quintini, Gianluca
Gnad-Vogt, Senta Ulrike
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL
Codo, Paula
Eigentler, Thomas
Heinzerling, Lucie
Krauss, Juergen
Weishaupt, Carsten
Ochsenreither, Sebastian
Lebbe, Celeste
Mohr, Peter
Oliva, Marc
Oberoi, Honey
Terheyden, Patrick
Perez, Jose Trigo
Bauernfeind, Franz-Georg
Fluck, Michael
Richtig, Erika
Soria, Ainara
Gonzalez, Marina
Funkner, Fatma
Wengenmayer, Peter
Vahrenhorst, Dominik
Seibel, Tobias
Quintini, Gianluca
Schmitt-Bormann, Beate
Scheel, Birgit
Falk, Martin
Gnad-Vogt, Ulrike
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A502 - A502
[4] A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours
Krauss, J.
Eigentler, T.
Schreiber, J.
Weishaupt, C.
Terheyden, P.
Heinzerling, L.
Mohr, P.
Weide, B.
Ochsenreither, S.
Gutzmer, R.
Becker, J. C.
Kiecker, F.
Funkner, F.
Heidenreich, R.
Kays, S-K.
Klinkhardt, U.
Gnad-Vogt, U. S.
Scheel, B.
Schoenborn-Kellenberger, O.
Seibel, T.
ANNALS OF ONCOLOGY, 2019, 30 : 191 - +
[5] Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008
Eigentler, T.
Heinzerling, L.
Krauss, J.
Weishaupt, C.
Ochsenreither, S.
Lebbe, C.
Mohr, P.
Oliva, M.
Oberoi, H. K.
Terheyden, P.
Perez, J. M. Trigo
Robert, C.
Bauernfeind, F-G.
Fluck, M.
Richtig, E.
Soria, A.
Kays, S-K.
Schmitt-Bormann, B.
Falk, M.
Gnad-Vogt, U. S.
ANNALS OF ONCOLOGY, 2021, 32 : S853 - S853
[6] IMMUNE PROFILING OF PATIENTS WITH ADVANCED MELANOMA INTRATUMORALLY TREATED WITH CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTIPD-1 ANTIBODIES - RESULTS OF A PHASE I TRIAL EXPANSION
Gonzalez, Marina
Wengenmayer, Peter
Samoylenko, Igor
Ochsenreither, Sebastian
Richtig, Erika
Thomas, Ioannis
Erdmann, Michael
Lebbe, Celeste
Martin-Liberal, Juan
Terheyden, Patrick
Poltoratskiy, Artem
Sekacheva, Marina
Semiletova, Yuliya
Eigentler, Thomas
Schmitt-Bormann, Beate
Vahrenhorst, Dominik
Kays, Sarah-Katharina
Seibel, Tobias
Quintini, Gianluca
Scheel, Birgit
Falk, Martin
Gnad-Vogt, Ulrike
Codo, Paula
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A816 - A816
[7] INTRATUMORALLY ADMINISTERED CV8102 IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY RESULTS FROM ONGOING EXPANSION PART IN STUDY 008
Eigentler, Thomas
Samoylenko, Igor
Ochsenreither, Sebastian
Richtig, Erika
Thomas, Ioannis
Erdmann, Michael
Lebbe, Celeste
Soto-Castillo, Juan Jose
Terheyden, Patrick
Poltoratskiy, Artem
Sekacheva, Marina
Semiletova, Yuliya
Henze, Janina
Schmitt-Bormann, Beate
Codo, Paula
Falk, Martin
Gnad-Vogt, Ulrike
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A818 - A818
[8] Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors
Eigentler, Thomas
Krauss, Juergen
Schreiber, Jutta
Weishaupt, Carsten
Terheyden, Patrick
Heinzerling, Lucie
Mohr, Peter
Weide, Benjamin
Gutzmer, Ralf
Becker, Juergen C.
Kiecker, Felix
Daehling, Angelika
Funkner, Fatma
Heidenreich, Regina
Kays, Sarah-Katharina
Klinkhardt, Ute
Scheel, Birgit
Schoenborn-Kellenberger, Oliver
Seibel, Tobias
Stosnach, Claudia
Strack, Tanja
Gnad-Vogt, Ulrike
CANCER RESEARCH, 2019, 79 (13)
[9] Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors
Terheyden, P.
Weishaupt, C.
Heinzerling, L.
Klinkhardt, U.
Krauss, J.
Mohr, P.
Kiecker, F.
Becker, J. C.
Submitter, A. Daehling
Doener, F.
Heidenreich, R.
Scheel, B.
Schoenborn-Kellenberger, O.
Seibel, T.
Gnad-Vogt, U.
ANNALS OF ONCOLOGY, 2018, 29 : 466 - 466
[10] Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors
Nishikawa, Tadaaki
Matsumoto, Koji
Tamura, Kenji
Yoshida, Hiroyuki
Imai, Yuichi
Miyasaka, Aki
Onoe, Takuma
Yamaguchi, Satoshi
Shimizu, Chikako
Yonemori, Kan
Shimoi, Tatsunori
Yunokawa, Mayu
Xiong, Hao
Nuthalapati, Silpa
Hashiba, Hideyuki
Kiriyama, Tsukasa
Leahy, Terri
Komarnitsky, Philip
Fujiwara, Keiichi
CANCER SCIENCE, 2017, 108 (09) : 1834 - 1842

← 1 2 3 4 5 →